Skip to main content
SpringerLink
Log in

Pharmacological and Pharmacokinetic Basis of Chlamydia pneumoniae Treatment

  • Chapter
Book cover Chlamydia Pneumoniae Infection

  • 35 Accesses

Abstract

Chlamydia pneumoniae,such as other Chlamydia species, is an obligate intracellular parasite. To inhibit its growth it is necessary that the antimicrobial agent penetrates cells and can interfere with protein synthesis of the micro-organism. Therefore antibiotics that are likely to be active against Chlamydia pneumoniae are macrolides, tetracyclines, chloramphenicol, quinolones and rifampicin, which have demonstrated the capacity to enter cells and develop antimicrobial activity intracellularly for Chlamydia psittaci and Chlamydia trachomatis, as well as for other pathogens.

This is a preview of subscription content, log in via an institution to check access.

Access this chapter

Log in via an institution
Chapter
USD 29.95
Price excludes VAT (USA)
  • Available as PDF
  • Read on any device
  • Instant download
  • Own it forever
eBook
USD 39.99
Price excludes VAT (USA)
  • Available as EPUB and PDF
  • Read on any device
  • Instant download
  • Own it forever
Softcover Book
USD 54.99
Price excludes VAT (USA)
  • Compact, lightweight edition
  • Dispatched in 3 to 5 business days
  • Free shipping worldwide - see info

Tax calculation will be finalised at checkout

Purchases are for personal use only

Institutional subscriptions

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. Johnson JD, Hand WL, Francis JB, King-Thompson NK, Corwin RW (1980) Antibiotic uptake by alveolar macrophages. J Lab Clin Med 95: 429–439

    PubMed  CAS  Google Scholar 

  2. Prokesch RC, Hand WL (1982) Antibiotic entry into polymorphonuclear leukocytes. Antimicrob Agents Chemother 21: 373–380

    PubMed  CAS  Google Scholar 

  3. Tulkens PM (1991) Intracellular pharmacokinetics and localization of antibiotics as predictors of their efficacy against intraphagocytic infections. Scand J Infect Dis [Suppl 741: 209–217

    Google Scholar 

  4. Tulkens PM (1991) Intracellular distribution and activity of antibiotics. Eur J Clin Infect Dis 10 (2): 100–106

    Article  CAS  Google Scholar 

  5. Peters DH, Clissod SP (1992) Clarithromycin. A review of its antimicrobial activity, pharmacokinetic property and therapeutic potential. Drugs 44: 117–164

    Google Scholar 

  6. Cartier MB, Zenebergh A, Tulkens PM (1987) Cellular uptake and subcellular distribution of roxithromycin and erythromycin in phagocytic cells. J Antimicrob Chemother 20 [Suppl B1: 47–56

    Google Scholar 

  7. Fraschini F, Scaglione F, Pintucci, G Maccarinelli G et al (1991) The diffusion of clarithromycin and roxithromycin into nasal mucosa, tonsil and in lung in humans. J Antimicrob Chemother 27 [Suppl A]: 61–65

    PubMed  Google Scholar 

  8. Bergogne-Bérézin E (1993) Tissue distribution of dirithromycin: comparison with erythromycin. J Antimicrob Chemother 31 [Suppl C]: 77–87

    PubMed  Google Scholar 

  9. Anderson R, Joone G, van Rensburg CEJ (1988) An in vitro evaluation of the cellular uptake and intraphagocytic bioactivity of clarithromycin (A-56268, TE-031), a new macrolide antimicrobial agent. J Antimicrobial Chemother 22: 923–933

    Article  CAS  Google Scholar 

  10. MacDonald PJ, Pruul H (1991) Phagocyte uptake and transport of azithromycin. Eur J Clin Microbiol Infect Dis 10: 828–833

    Article  Google Scholar 

  11. Foulds G, Shepard RM, Johnson RB (1990) The pharmacokinetics of azithromycin in human serum and tissues. J Antimicrob Chemother 25 [Suppl A1: 73–82

    Google Scholar 

  12. Bergogne-Bérézin E (1981) Penetration of antibiotics into the respiratory tree. J Antimicrob Chemother 8: 171–174

    Article  PubMed  Google Scholar 

  13. Smith BR, LeFrock JL (1983) Bronchial tree penetration of antibiotic. Chest 83(6): 904908

    Google Scholar 

  14. Valcke Y, Pauwels R, Van Den Straeten M (1990) Pharmacokinetics of antibiotics in the lung. Eur Respir J 3: 715–722

    PubMed  CAS  Google Scholar 

  15. Baldwin DR, Honeybourne D, Wise R (1992) Pulmonary disposition of antimicrobial agents: in vivo observations and clinical relevance. Antimicrob Agents and Chemother 36 (6): 1176–1180

    CAS  Google Scholar 

  16. Gialdroni Grassi G (1980) Passaggio degli antibiotici nelle secrezioni bronchiali. In: Gialdroni Grassi G and Grassi C (eds). Aggiornamenti di chemioterapia. La Goliardica Pavese Publ., Pavia, pp 68–88

    Google Scholar 

  17. Gerdin DN, H.H.J.A (1989) Tissue penetration of the new quinolones in humans. Rev Infect Dis 11 [Suppl 5]: S1046 - S1057

    Google Scholar 

  18. Baldwin DR, Wise R, Andrews JM, Ashby JP et al (1990) Azithromycin concentrations at the sites of pulmonary infection. Eur Respir J 3: 886–890

    PubMed  CAS  Google Scholar 

  19. Andrews JM, Honeybourne D, Greaves I, Baldwin D et al (1992) Clarithromycin levels in human bronchial mucosa, alveolar macrophages and serum. 8th Mediterranean Congress of Chemotherapy Athens, Greece Abs. 714

    Google Scholar 

  20. Baldwin DR, Honeybourne D, Wise R (1992) Pulmonary disposition of antimicrobial agents: methodological consideration. Antimicrob Agents Chemother 36: 1171–1175

    PubMed  CAS  Google Scholar 

  21. Gump DW (1991) Antimicrobial susceptibility testing for some atypical microrganisms: Chlamydiae, Mycoplasms, Rickettsia, and Spirochetes. In: Lorian V (ed) Antibiotic in laboratory medicine. 3rd Ed, Williams & Wilkins, pp 279–294

    Google Scholar 

  22. Welsh LE, Gaydos CA, Quinn TC (1992) In vitro evaluation of activities of azithromycin, erythromycin and tetracyclines against Chlamydia trachomatis and Chlamydia pneumoniae Antimicrob Agents Chemother 36:291–294

    Google Scholar 

  23. Cooper MA, Baldwin D, Matthews RS, Andrews JM, Wise R (1991) In vitro susceptibility of Chlamydia pneumoniae ( TWAR) to seven antibiotics. J Antimicrob Chemother 2: 407–413

    Google Scholar 

  24. Roblin PM, Hammerschlag MR (1990) In vitro activity of sparfloxacin (CI-978, AT 4140) and other quinolones against Chlamydia trachomatis and Chlamydia pneumoniae. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, Atlanta Abs 22

    Google Scholar 

  25. Kuo CC, Grayston JT (1988) In vitro drug susceptibility of Chlamydia sp. strain TWAR. Antimicrob Agents Chemother 32:257–258

    Google Scholar 

  26. Atmar RL, Greenberg SB (1989) Pneumonia caused by Mycoplasma pneumoniae and the TWAR agent. Seminars in Respiratory Infections 4: 19–31

    PubMed  CAS  Google Scholar 

  27. Bourke SJ (1993) Chlamydial respiratory infections. British Med J 306: 1219–1220

    Article  CAS  Google Scholar 

  28. Fenelon LE, Mumtaz G, Ridgway GL (1990) The in vitro susceptibility of Chlamydia pneumoniae. J Antimicrob Chemother 26: 763–767

    Article  PubMed  CAS  Google Scholar 

  29. Chirwing K, Roblin PM, Hammerschlag MR (1989) In vitro susceptibilities of Chlamydia pneumoniae Antimicrob Agents Chemother 1634–1635

    Google Scholar 

  30. Orfila J, Haider F (1992) In vitro susceptibilities of Chlamydia pneumoniae strain IOL 207 against clarithromycin, compared to different molecules. In: Adam D, Lode H, Rubinstein E (eds) Recent Advances in Chemotherapy. Proceedings of the 17th International Congress of Chemotherapy Berlin, Futuramed Publisher, Munich, Germany, pp 2454–2455

    Google Scholar 

  31. Hammerschlag MR, Qumei KK, Roblin PM (1992) In vitro activities of azithromycin, clarithromycin, L-ofloxacin and other antibiotics against Chlamydia pneumoniae Antimicrob Agents Chemother 36:1573–1574

    Google Scholar 

  32. Soejima R, Niki Y, Kishimoto T, Kimura M, Kubota Y (1994) Anti-chlamydial activities of newly developed fluoroquinolones and their clinical usefulness for Chlamydia respiratory infections. 5th Int Symposium on new quinolones, Singapore, Abs 135

    Google Scholar 

  33. Ridgway GL, Mumtaz G, Fenelon L (1991) In vitro activity of clarithromycin and other macrolides against the type strain of Chlamydia pneumoniae J Antimicrob Chemother 27 [Suppl A1:43–45

    Google Scholar 

  34. Roblin PM, Montalban G, Hammerschlag MR (1994) Susceptibilities of isolates of Chlamydia pneumoniae from children with pneumonia to clarithromycin and erythromycin. 2nd International Conference on the macrolides, azalides and streptogamins, Venice, Italy, Abs 150

    Google Scholar 

  35. Orfila F, Haider F (1990) In vitro susceptibility of Chlamydia pneumoniae (strain IOL 207) against a new fluoroquinolone, sparfloxacin, compared to different other molecules. 30th Interscience Conference on Antimicrobial Agents and Chemotherapy, ICAAC, Atlanta, Georgia, October 21–24, 1990, Abs 18

    Google Scholar 

  36. Hammerschlag MR, Hyman CL, Roblin PM (1992) In vitro activities of five quinolones against Chlamydia pneumoniae Antimicrob Agents Chemother 36:682–683

    Google Scholar 

  37. Orfila J, Haider F (1992) In vitro susceptibility of Chlamydia pneumoniae strain IOL 207 against temafloxacin compared to different other molecules. In: Adam D, Lode H, Rubinstein E (eds) Recent Advances in Chemotherapy. Proceedings of the 17th International Congress of Chemotherapy, Berlin 1991, vol II, pp 2344–45, Futuramed Publisher, Munich, Germany

    Google Scholar 

  38. Andrews JM, Wise R, Brenwald N (1993) In vitro activity of BAY3118. VI Eur Congress Clin Microbiol and Infect Dis, Seville, March 28–31, 1993, Abs 4

    Google Scholar 

  39. Roblin PM, Montalban G, Hammerschlag MR (1994) In vitro activities of OPC-17116, a new quinolone, ofloxacin and sparfloxacin against Chlamydia pneumoniae Antimicrob Agents Chemother 38:1402–1403

    Google Scholar 

  40. Dumornay W, Mandel L, Smith P, Schacter J (1992) Persistent infection with Chlamydia pneumoniae following acute respiratory illness. Clin Infect Dis 14: 178–182

    Article  PubMed  Google Scholar 

  41. Kobayashi H (1986) Clinical evaluation of ofloxacin in lower respiratory tract infections. Infection 14 [Suppl4]: S279–5282

    Article  PubMed  Google Scholar 

  42. Lipsky BA, Tack KJ, Kuo CC, Wang SP (1990) Ofloxacin treatment of Chlamydia pneumoniae (strain TWAR) lower respiratory tract infections. Am J Med 89: 722–724

    Article  PubMed  CAS  Google Scholar 

  43. Nakata K, Okazaki Y, Hattori H, Nakamura S (1994) Protective effect of sparfloxacin in experimental pneumonia caused by Chlamydia pneumoniae in leukopenic mice. Antimicrob Agents Chemother 38: 1757–1762

    PubMed  CAS  Google Scholar 

  44. Aubier M, Garau J, Geslin P, Grassi C, Hosie G, Huchon G, Legakis N, Lode H, Regamey C and the European Study Group (1994) Sparfloxacin: an empiric therapy in community-acquired pneumonia. A meta-analysis of two comparative studies. 6th Int Congress for Infect Dis, Prague, April 26–30, 1994, Abs 459

    Google Scholar 

Download references

Authors
  1. Giuliana Gialdroni Grassi
    View author publications

    You can also search for this author in PubMed Google Scholar

Editor information

Editors and Affiliations

  1. University of Milan, Via Francesco Sforza 35, Milan, Italy

    Luigi Allegra M.D. (Head of the Institute of Respiratory Diseases) (Head of the Institute of Respiratory Diseases)

  2. Institute of Respiratory Diseases, University of Milan, Via Francesco Sforza 35, Milan, Italy

    Francesco Blasi M.D., PH.D. (Assistant Professor) (Assistant Professor)

Rights and permissions

Reprints and permissions

Copyright information

© 1995 Springer-Verlag Italia, Milano

About this chapter

Cite this chapter

Grassi, G.G. (1995). Pharmacological and Pharmacokinetic Basis of Chlamydia pneumoniae Treatment. In: Allegra, L., Blasi, F. (eds) Chlamydia Pneumoniae Infection. Springer, Milano. https://doi.org/10.1007/978-88-470-2201-0_5

Download citation

  • DOI: https://doi.org/10.1007/978-88-470-2201-0_5

  • Publisher Name: Springer, Milano

  • Print ISBN: 978-3-540-75007-9

  • Online ISBN: 978-88-470-2201-0

  • eBook Packages: Springer Book Archive

Publish with us

Policies and ethics

Search

Navigation